A Phase 2 interventional study of KPS-0373 and Placebo in Spinocerebellar Degeneration, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-09-28.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Spinocerebellar Degenerations with a site in Japan — none open to participants now, 1 under way, 1 of them phase 3. Spinocerebellar Degenerations · Japan.
Among the 11 studies in Spinocerebellar Degenerations with a site in Japan, this one is one of 4 in phase 2, and was the 2nd registered.
49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.
Browse Spinocerebellar Degenerations studies →None of the 11 studies in Spinocerebellar Degenerations with a site in Japan is open now. The open studies under Spinocerebellar Degenerations, anywhere →
Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 45 across 36 interventional studies indexed under Spinocerebellar Degenerations.
Median enrollment 202 across the 8 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 9 studies filed under Spinocerebellar Degenerations — fewer than ten, so there is no comparison to draw.
1 of the studies in Spinocerebellar Degenerations with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07040137Phase 3Kissei Pharmaceutical Co., Ltd.Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Spinocerebellar Degenerations with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of KPS-0373 in patients with SCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: KPS-0373
Scale for Assessment and Rating of Ataxia (SARA)
Time frame: 4 weeks + 12 weeks
Upper and lower extremity function
Time frame: 4 weeks + 12 weeks
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rovatirelin
Spinocerebellar Degenerations →
Kissei Pharmaceutical Co., Ltd. →